Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Clovis said FDA granted breakthrough therapy designation to CO-1686 as monotherapy for second-line treatment of non-small cell lung cancer (NSCLC) in patients with the T790M EGFR resistance mutation....
